206 related articles for article (PubMed ID: 35920264)
1. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
3. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
4. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
5. Performing Precise Biopsy in Naive Patients With Equivocal PI-RADS, Version 2, Score 3, Lesions: An MRI-based Nomogram to Avoid Unnecessary Surgical Intervention.
Zhang Y; Zeng N; Zhang FB; Rui Huang YX; Tian Y
Clin Genitourin Cancer; 2020 Oct; 18(5):367-377. PubMed ID: 32771334
[TBL] [Abstract][Full Text] [Related]
6. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy-naive men based on multi-institutional analysis.
Ge Q; Zhang S; Xu H; Zhang J; Fan Z; Li W; Shen D; Xiao J; Wei Z
Cancer Med; 2023 Dec; 12(24):21820-21829. PubMed ID: 38014481
[TBL] [Abstract][Full Text] [Related]
8. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
[No Abstract] [Full Text] [Related]
9. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
[TBL] [Abstract][Full Text] [Related]
10. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
11. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
12. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
13. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
14. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.
Chen S; Yang Y; Peng T; Yu X; Deng H; Guo Z
Int J Med Sci; 2020; 17(10):1366-1374. PubMed ID: 32624693
[No Abstract] [Full Text] [Related]
15. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
16. Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.
Arafa MA; Farhat KH; Khan FK; Rabah DM; Elmorshedy H; Mokhtar A; Al-Taweel W
Prostate; 2024 Jan; 84(1):56-63. PubMed ID: 37759243
[TBL] [Abstract][Full Text] [Related]
17. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
Cheng Y; Fan B; Fu Y; Yin H; Lu J; Li D; Li X; Qiu X; Guo H
BMC Urol; 2024 Apr; 24(1):76. PubMed ID: 38566091
[TBL] [Abstract][Full Text] [Related]
18. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.
Sun J; Zhang Z; OuYang J
Urol Oncol; 2020 May; 38(5):401-409. PubMed ID: 31870724
[TBL] [Abstract][Full Text] [Related]
19. Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data.
Tao T; Wang C; Liu W; Yuan L; Ge Q; Zhang L; He B; Wang L; Wang L; Xiang C; Wang H; Chen S; Xiao J
Front Oncol; 2021; 11():811866. PubMed ID: 35127526
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]